112 related articles for article (PubMed ID: 29573027)
1. BRAF
Kim HK; Lee I; Lee J; Chang HS; Soh EY; Park IS; Kim JH; Rho YS; Lee DJ
Head Neck; 2018 Aug; 40(8):1707-1718. PubMed ID: 29573027
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
Pool C; Walter V; Bann D; Goldenberg D; Broach J; Hennessy M; Cottrill E; Washburn E; Williams N; Crist H; Imamura Y; Warrick JI
Virchows Arch; 2019 Mar; 474(3):341-351. PubMed ID: 30645670
[TBL] [Abstract][Full Text] [Related]
3. Association of Polygenic Score With Tumor Molecular Subtypes in Papillary Thyroid Carcinoma.
Wang JR; Zafereo ME; Wang W; Joshu C; Ray D
J Clin Endocrinol Metab; 2023 Dec; 109(1):e306-e313. PubMed ID: 37453101
[TBL] [Abstract][Full Text] [Related]
4. Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.
Chai YJ; Yi JW; Jee HG; Kim YA; Kim JH; Xing M; Lee KE
PLoS One; 2016; 11(7):e0159235. PubMed ID: 27410688
[TBL] [Abstract][Full Text] [Related]
5. BRAF-positive multifocal and unifocal papillary thyroid cancer show different messenger RNA expressions.
Pak K; Suh S; Goh TS; Kim SJ; Oh SO; Seok JW; Kim IJ; Kim YH
Clin Endocrinol (Oxf); 2019 Apr; 90(4):601-607. PubMed ID: 30592330
[TBL] [Abstract][Full Text] [Related]
6. Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.
Rosignolo F; Maggisano V; Sponziello M; Celano M; Di Gioia CR; D'Agostino M; Giacomelli L; Verrienti A; Dima M; Pecce V; Durante C
J Endocrinol Invest; 2015 Dec; 38(12):1283-9. PubMed ID: 26003825
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score.
Boucai L; Seshan V; Williams M; Knauf JA; Saqcena M; Ghossein RA; Fagin JA
J Clin Endocrinol Metab; 2022 Mar; 107(4):1030-1039. PubMed ID: 34897468
[TBL] [Abstract][Full Text] [Related]
8. BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.
Durante C; Tallini G; Puxeddu E; Sponziello M; Moretti S; Ligorio C; Cavaliere A; Rhoden KJ; Verrienti A; Maranghi M; Giacomelli L; Russo D; Filetti S
Eur J Endocrinol; 2011 Sep; 165(3):455-63. PubMed ID: 21653734
[TBL] [Abstract][Full Text] [Related]
9. LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.
Pinheiro Dos Santos MJC; Bastos AU; da Costa VR; Delcelo R; Lindsey SC; Colozza-Gama GA; Peng H; Rauscher FJ; Oler G; Cerutti JM
Endocr Pathol; 2018 Sep; 29(3):222-230. PubMed ID: 29560564
[TBL] [Abstract][Full Text] [Related]
10. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
[TBL] [Abstract][Full Text] [Related]
11. BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma.
Rusinek D; Swierniak M; Chmielik E; Kowal M; Kowalska M; Cyplinska R; Czarniecka A; Piglowski W; Korfanty J; Chekan M; Krajewska J; Szpak-Ulczok S; Jarzab M; Widlak W; Jarzab B
PLoS One; 2015; 10(12):e0143688. PubMed ID: 26625260
[TBL] [Abstract][Full Text] [Related]
12. Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability.
Hong S; Xie Y; Cheng Z; Li J; He W; Guo Z; Zhang Q; Peng S; He M; Yu S; Xu L; Liu R; Xu T; Zhang Y; Li Y; Wang J; Lv W; Yu J; Xiao H
Oncogene; 2022 Nov; 41(47):5121-5132. PubMed ID: 36253446
[TBL] [Abstract][Full Text] [Related]
13. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
14. Role of BRAF and RAS Mutations in Extrathyroidal Extension in Papillary Thyroid Cancer.
Park JY; Yi JW; Park CH; Lim Y; Lee KH; Lee KE; Kim JH
Cancer Genomics Proteomics; 2016; 13(2):171-81. PubMed ID: 26912807
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
[TBL] [Abstract][Full Text] [Related]
16. Imbalance in DNA repair machinery is associated with BRAF
Lutz BS; Leguisamo NM; Cabral NK; Gloria HC; Reiter KC; Agnes G; Zanella V; Meyer ELS; Saffi J
Mol Cell Endocrinol; 2018 Sep; 472():140-148. PubMed ID: 29229408
[TBL] [Abstract][Full Text] [Related]
17. LncRNA ENST00000539653 acts as an oncogenic factor via MAPK signalling in papillary thyroid cancer.
Song B; Li R; Zuo Z; Tan J; Liu L; Ding D; Lu Y; Hou D
BMC Cancer; 2019 Apr; 19(1):297. PubMed ID: 30940124
[TBL] [Abstract][Full Text] [Related]
18. Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA; Riemann B; Hartmann MJM; Michel M; Faust M; Bruns CJ; Alakus H; Chiapponi C
Front Endocrinol (Lausanne); 2021; 12():748941. PubMed ID: 34630336
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of BRAF mutation in thyroid papillary cancer.
Fernandez IJ; Piccin O; Sciascia S; Cavicchi O; Repaci A; Vicennati V; Fiorentino M
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):919-25. PubMed ID: 23482475
[TBL] [Abstract][Full Text] [Related]
20. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
Zhang J; Yang Y; Zhao J; Shi L; Xu Y; Yu K; Guo C
Pathol Res Pract; 2019 Apr; 215(4):761-765. PubMed ID: 30819583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
